| Bioactivity | AS1708727 is an orally active Foxo1 inhibitor, with EC50 values of 0.33 μM and 0.59 μM for G6Pase and PEPCK, respectively[1]. | ||||||||||||
| Invitro | AS1708727 suppresses increases in blood glucose level by inhibiting gluconeogenic gene expression[1]. RT-PCR[1] Cell Line: | ||||||||||||
| In Vivo | AS1708727 (30 to 300 mg/kg, orally) reduces both blood glucose and triglyceride levels, exhibiting anti-diabetic effects[1]. Animal Model: | ||||||||||||
| Name | AS1708727 | ||||||||||||
| CAS | 1253226-93-5 | ||||||||||||
| Formula | C24H24Cl2N2O2 | ||||||||||||
| Molar Mass | 443.37 | ||||||||||||
| Appearance | Solid | ||||||||||||
| Transport | Room temperature in continental US; may vary elsewhere. | ||||||||||||
| Storage |
|
||||||||||||
| Reference | [1]. Hirotsugu Tanaka, et al. Effects of the Novel Foxo1 Inhibitor AS1708727 on Plasma Glucose and Triglyceride Levels in Diabetic Db/Db Mice. Eur J Pharmacol. 2010 Oct 25;645(1-3):185-91. |
AS1708727
CAS: 1253226-93-5 F: C24H24Cl2N2O2 W: 443.37
AS1708727 is an orally active Foxo1 inhibitor, with EC50 values of 0.33 μM and 0.59 μM for G6Pase and PEPCK, respectiv
Sales Email：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.